<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225026</url>
  </required_header>
  <id_info>
    <org_study_id>GTI-4419-203</org_study_id>
    <nct_id>NCT04225026</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer</brief_title>
  <official_title>A Phase 2a Open-Label Trial of the Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis in Subjects Receiving Chemoradiotherapy for Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Galera Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Galera Therapeutics, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      GTI-4419-203 will be an open-label, multi-center study to evaluate GC4419 administered
      intravenous (IV) for the reduction of radiation induced esophagitis in subjects receiving
      chemoradiotherapy for unresectable Stage 3A/3B or post-operative Stage 2B NSCLC, SCLC
      treatable with chemoradiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of acute radiation esophagitis</measure>
    <time_frame>From the first RT fraction through the end of the study treatment period, which is estimated to be 6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Esophagitis</condition>
  <arm_group>
    <arm_group_label>GC4419</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GC4419</intervention_name>
    <description>90 mg, by 60-minute IV infusion, prior to each fraction of RT</description>
    <arm_group_label>GC4419</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects scheduled to be treated with (definitive or adjuvant) radiation therapy in
             combination with chemotherapy once daily for Stage 3A/3B or post-operative Stage 2B
             NSCLC or limited stage SCLC

          2. Treatment plan for subjects show that 5 cm of the esophagus for at least one surface,
             is included in the 60 Gy isodose volume. Dose volume histograms show esophagus dose
             exposure meet V38&gt;30% and/or V60&gt;20%

          3. Age 18 years or older

          4. ECOG performance status â‰¤ 2

          5. Adequate hematologic, renal and liver function

          6. Use of highly effective contraception

        Exclusion Criteria:

          1. Metastatic disease

          2. Prior radiation therapy to the region of the study cancer

          3. Subjects not receiving chemotherapy

          4. Grade 2 or greater esophagitis at baseline

          5. Inability to provide information in the electronic symptom-reporting device

          6. Receiving any approved or investigational immunotherapy, targeted therapy, hormone
             therapy, or biologic therapy

          7. Participation in another clinical trial or use of another investigational agent within
             30 days of first does of GC4419

          8. Malignant tumors other than the current lung cancer within the last 5 years

          9. Previous diagnosis of pneumonitis

         10. Untreated, active infectious disease requiring systemic anti-infective therapy

         11. Untreated HIV or active hepatitis B/C

         12. Females who are pregnant or breastfeeding

         13. Known allergies or intolerance to chemotherapy and similar platinum-containing
             compounds

         14. Requirement for concurrent treatment with nitrates or other drugs that may create a
             risk for a precipitous decrease in blood pressure

         15. Clinically significant heart disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon T Holmlund, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chief Medical Officer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amanda Sanders</last_name>
    <phone>484-870-9622</phone>
    <email>asanders@galeratx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elliott White</last_name>
      <phone>813-844-4316</phone>
    </contact>
    <investigator>
      <last_name>Lawrence Berk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IACT Health</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grayson Scott</last_name>
      <phone>706-321-0495</phone>
    </contact>
    <investigator>
      <last_name>Douglas Ciuba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Hollenbeck</last_name>
      <phone>319-356-7611</phone>
    </contact>
    <investigator>
      <last_name>Bryan Allen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack Meridian Health</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07753</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Doherty</last_name>
      <phone>732-776-3466</phone>
    </contact>
    <investigator>
      <last_name>Douglas Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Kenrick</last_name>
      <phone>864-603-6216</phone>
    </contact>
    <investigator>
      <last_name>Robert Siegel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional Medical Center - Gibbs Cancer Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Stanley</last_name>
      <phone>864-560-7252</phone>
    </contact>
    <investigator>
      <last_name>Amarintha Curtis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Medical Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenna Adelman</last_name>
      <phone>865-305-5131</phone>
    </contact>
    <investigator>
      <last_name>Joseph Kelley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Regional Cancer Partnership</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Nichols</last_name>
      <phone>425-261-3544</phone>
    </contact>
    <investigator>
      <last_name>William Wisbeck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophagitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

